Ad
related to: cd22 positive b cell
Search results
Results from the WOW.Com Content Network
CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. [4] It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases. [5]
The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38. [5] This toxin is a 38 kDa fragment of Pseudomonas exotoxin A. Hairy cell leukemia (HCL) is a rare, slow-growing cancer of the blood in which the bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection ...
Inotuzumab ozogamicin is used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia. [4] [5]In March 2024, the FDA approved inotuzumab ozogamicin for the treatment of children aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
Like CD19, CD22 is a cell surface marker for lymphocytes that is present on most B cell malignancies, including acute lymphoblastic leukemia and various subtypes of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma. CD22 expression has been shown to be maintained in acute lymphoblastic leukemia that has lost CD19, making anti-CD22 a ...
This creates an activation threshold for B cell activation whereby transient activation of B cells is prevented. [13] CD22 inhibition of BCR signalling was originally thought to be sialic acid-binding-independent, but evidence suggests α2,6 sialic acid ligands are required for inhibition. [14] Siglec-7 is found on Natural Killer cells (NK ...
B cells, also known as B lymphocytes, are a type of white blood cell of the lymphocyte subtype. [1] They function in the humoral immunity component of the adaptive immune system. [1] B cells produce antibody molecules which may be either secreted or inserted into the plasma membrane where they serve as a part of B-cell receptors. [2]
The European Commission approved Inotuzumab ozogamicin [15] as a monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) on June 30, 2017 under the trade name Besponsa® (Pfizer/Wyeth), [16] followed on August 17, 2017 by the FDA.
An anti-CD22 immunotoxin is a monoclonal antibody targeting CD22 linked to a cytotoxic agent. As of August 2009, it was studied in the treatment of some types of B-cell cancer. It binds to CD22, a receptor protein on the surface of normal B cells and B-cell tumors, and, upon internalization, kills the cells, acting as immunotoxin.
Ad
related to: cd22 positive b cell